Zentalis Pharmaceuticals
ZNTL
128 hedge funds and large institutions have $2.03B invested in Zentalis Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 47 increasing their positions, 48 reducing their positions, and 26 closing their positions.
391% more call options, than puts
Call options by funds: $6.79M | Put options by funds: $1.38M
2.66% more ownership
Funds ownership: 94.88% → 97.54% (+2.7%)
2% less repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 48
8% less funds holding
Funds holding: 139 → 128 (-11)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
38% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 26
43% less capital invested
Capital invested by funds: $3.58B → $2.03B (-$1.55B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$39.6M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$24.9M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$12.5M |
| 4 |
Morgan Stanley
New York
|
+$7.97M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$7.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$17.7M |
| 2 |
Holocene Advisors
New York
|
-$16M |
| 3 |
TCM
Tybourne Capital Management
Hong Kong
|
-$10.9M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.96M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$6.56M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | -$647 | -12 | -63% |
|
|
C
152
Covestor
London,
United Kingdom
| – | -$108 | -2 | -20% |
|
|
JWA
153
JFS Wealth Advisors
Hermitage,
Pennsylvania
| – | +$54 | +1 | New |
|
|
MFT
154
Moisand Fitzgerald Tamayo
Orlando,
Florida
| – | +$432 | +8 | New |
|
ZNTL Hedge Fund Activity: Q1 2022 in Review
128 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q1 2022, worth a combined $2.03B — down 43% from $3.58B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of ZNTL and 16 opened new positions — a net loss of 10 holders — while 48 trimmed existing stakes and 47 added.
The largest buyer was State Street, adding an estimated $39.6M. The largest seller was Woodline Partners, cutting an estimated $17.7M.
- 128 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q1 2022, down from 139 in Q4 2021.
- Funds reported $2.03B of Zentalis Pharmaceuticals stock for Q1 2022, down 43% quarter-over-quarter.
- 16 funds opened new Zentalis Pharmaceuticals positions in Q1 2022 and 26 closed out, a net change of -10 holders.
- The largest Zentalis Pharmaceuticals buyer in Q1 2022 was State Street, an estimated $39.6M added.
- The largest Zentalis Pharmaceuticals seller in Q1 2022 was Woodline Partners, an estimated $17.7M sold.
Based on aggregated 13F filings for Q1 2022.